Sandoz Completes Deal For Mycamine
Acquisition Of Antifungal Brand From Astellas Was Announced In Early 2023
Executive Summary
Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.